FDA RU 486 review: audit of foreign data requested in citizen petition filed by Rep. Bliley, pro-life group.
Executive Summary
FDA RU 486 REVIEW: FOREIGN DATA IN NDA MUST BE AUDITED, CITIZEN PETITION submitted to FDA Feb. 28 maintains. The petition was filed by Chicago-based "Americans United For Life" and several members of Congress including House Commerce Committee Chairman Bliley (R-Va.) and Judiciary Committee Chairman Hyde (R-Ill.). "The agency...should conduct in-depth validity audits of each foreign clinical trial relied upon by an RU 486 NDA applicant," the petition states.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth